Kisspeptins are peptide products of the KiSS-1 metastasis-suppressor (KISS1) gene and the natural ligands of the G-protein-coupled receptor GPR54. KISS1 was initially investigated as an antimetastasis gene. More recent studies have demonstrated that the kisspeptins are potent stimulators of the hypothalamo-pituitarygonadal axis. Mice and humans with defective kisspeptin signaling show hypogonadotrophic hypogonadism and impaired sexual development (1, 2 ) .
Plasma kisspeptin concentrations are Ͻ2 pmol/L in men and nonpregnant women. KiSS-1 mRNA is highly expressed in the placenta, and plasma kisspeptin concentrations increase dramatically, to thousands of picomoles per liter, during pregnancy (3 ) . In addition, plasma kisspeptin is increased in women with gestational trophoblastic tumors, thus raising the possibility of measuring plasma kisspeptin as a novel tumor marker (4 ) . Previous studies that have measured plasma kisspeptin in women during pregnancy have found significantly different concentrations of circulating kisspeptin (3, 4) that may be attributable to differences in preanalytical variables, such as collection tube type, processing times, and storage conditions.
Use of a standardized sample collection method for the mea- . Blood was collected, using a Vacutainer® system, directly into 4 tubes of each of the tube-types studied: lithium heparin with 2000 U/tube of trasylol (L), citrate (C), EDTA (E), serum clot-activator (S), and serum separator (SST) tubes (BD Vacutainer® Blood Collection Tubes). Both S and SST tubes are coated with silicone and micronized silicon particles to accelerate clotting. The SST tubes have, in addition, a barrier polymer at the bottom of the tube. The density of this polymer allows it to rise up to the clot-serum interface during centrifugation, thus forming a physical barrier separating the serum from the clot.
Of the 4 samples in each tube type, the first was processed immediately, and the second, third, and fourth samples were maintained at room temperature (18 -20°C) for 1, 2, and 4 h, respectively, before processing. All samples were processed by centrifugation at 4°C for 10 min at 855g. Serum and plasma were then aspirated, divided into aliquots, frozen, and stored at Ϫ80°C until assayed. Kisspeptin-IR was assayed using a specific RIA (5 ). The detection limit of the assay was 2 pmol/L of plasma kisspeptin-IR at a 95% confidence limit. The inter-and intraassay CVs were Ͻ11% and Ͻ9%, respectively. All samples were assayed in duplicate. Differences of means were assessed by paired t-test.
Kisspeptin-IR degraded rapidly in serum tubes. Kisspeptin-IR was undetectable in serum samples that were processed at t ϭ 1 h and later time points, and concentrations detected in serum samples processed immediately were significantly lower than those detected in plasma (P Ͻ0.05). Kisspeptin-IR concentrations in plasma samples collected in C tubes were consistently lower than those obtained from E and L collected samples, but this difference was not statistically significant (Table 1) . Kisspeptin-IR in plasma samples decreased with increased processing time, suggesting that kisspeptin-IR is best measured in plasma samples that are processed immediately after sampling.
To evaluate the effects of repeated freezing and thawing on plasma kisspeptin-IR concentrations, 5 mL of blood from each of 4 volunteers [age range 23-41 years, mean (SD) 30.5 (7.6) years; BMI 22-28, 25 (2.45); gestation 23-31 weeks, 30 (0.82) weeks] was collected directly into L and E collection tubes. L and E tubes were used, on the basis of results obtained in the first part of the study, which suggested that kisspeptin-IR was most stable in these 2 tube types. The samples were centrifuged and plasma was separated immediately after collection. An aliquot was taken from the plasma before the first cycle of freezing and after 1, 2, and 3 freeze-thaw cycles. Kisspeptin-IR concentrations in samples collected in L or E tubes did not significantly change even after 4 freeze-thaw cycles (data not shown).
Our studies suggest that circulating kisspeptin-IR concentrations should be measured in plasma samples processed immediately after collection. L or E tubes may preserve kisspeptin-IR better than C tubes. Repeated freezing and thawing does not significantly influence the measurement of kisspeptin-IR concentrations. 
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Relationship of MRIDetermined Infarct Size and cTnI Measurements in Patients with ST-Elevation Myocardial Infarction
To the Editor:
The extent of myocardial infarction (MI) is related to patient outcomes (1 ), and clinicians often wish to have a sense for this critical measure. Imaging methods, although accurate, have limited accessibility and high cost. Thus clinicians often use biomarkers to provide such an estimate. Measurement of cardiac troponin T (cTnT) at 96 h after onset of MI was observed to correlate with MRI-determined infarct size in both ST-elevation MI (STEMI) and non-STEMI (2 ). We tested the hypothesis that cardiac troponin I (cTnI), another myocardiumspecific biomarker, would provide an equivalent estimation in the subset of STEMI patients previously described (2 ) .
The 28 patients with STEMI had sufficient sample remaining to allow for determination of cTnI (2 ) . The characteristics of this group have previously been reported (2 ), but in brief the mean age (SD) was 56 (11) years, and 17.4% of patients were women. Mean (SD) body mass index was 26.46 (3.5) kg/m 2 , and 71.4% of patients were hypertensive, 64.3% were current smokers, 60.7% had hypercholesterolemia, and 14.3% had diabetes. Blood samples were available at admission and at 24, 48, 72, and 96 h after onset of symptoms. cTnI concentrations were measured at a laboratory in Heidelberg, Germany, with the AccuTnI assay (Beckman-Coulter). The assay has a limit of detection of 0.01 g/L, with a 99th percentile as low as 0.02-0.03 g/L. In the laboratory performing the measurements, a cutoff value of 0.03 g/L was used. Cardiac MRI was performed as described elsewhere (2 ) . Plasma concentrations of cTnI are reported as median with the corresponding interquartile range (IQR). For all analyses, a value of P Ͻ0.05 was considered statistically significant. Correlation coefficients were calculated by the Spearman test.
Of the 28 study patients with STEMI, 7.1% of patients (2 of 28) received fibrinolytic agents before percutaneous coronary intervention; the remainder underwent primary percutaneous coronary intervention.
Preinterventional thrombolysis in myocardial infarction flow grade 3 was present in 12 of 28 patients (42.3%) before PCI and in 27 of 28 patients (96.4%) after. The median time delay from onset of symptoms to balloon angioplasty was 6.25 h. MRI was performed at median of 4 days (range 3-4 days). All patients manifested delayed hyperenhancement observed with MRI; in 60.71% of patients (17 of 28) hyperenhancement was transmural. Mean infarct size relative to heart weight was 18.2% (IQR 7%-49%). Ventricular function evaluated by MRI revealed a mean ejection fraction of 54.4% (27.9%-63.6%) and a mean stroke volume of 91.32 mL (42.4 -109.3 mL). The median absolute value for infarct size was 29.3 g (IQR 16.6 -53.0 g). Spearman analysis demonstrated a strong correlation between cTnI values and infarct mass at 24 (n ϭ 24), 48 (n ϭ 26), 72 (n ϭ 23), and 96 h (n ϭ 28) after onset of symptoms ( Fig. 1A and B). As with other studies (2, 3 ) , correlations between the infarct size and cTnI were significant for all time-points except for admission (Spearman correlation coefficient Rho ϭ 0.2; data not shown).
These data document that cTnI values provide accurate estimates of infarct size in patients with STEMI. As with cTnT (2, 3 ), cTnI correlated with infarct size in reperfused STEMI patients at 24 -96 h as well (Fig. 1A) . These data indicate that clinicians can rely on values on days 1-4 to provide an approximation to MRIdetermined reperfused infarct size. Importantly, the slopes of the correlation curves are different for each day (Fig. 1B) . The parallelism of these data with the data for cTnT suggest that similar relationships, as with cTnT, are also likely to occur with non-STEMI. It is also likely that there will be differences with and without reperfusion. 
B-type natriuretic peptide (BNP) is a 32 amino acid cardiacsynthesized hormone that reduces blood pressure and increases sodium excretion (1 ) . Following proteolytic cleavage of proBNP, a 108-amino acid precursor, an Nterminal fragment (NT-proBNP) and BNP are released (2 ). Increased concentrations of BNP and NT-proBNP can be used clinically to monitor heart failure, but a lack of alignment between commercial BNP and NT-proBNP assays (3 ) can lead to confusion when clinicians or laboratorians compare results measured for the same analyte on different instruments. Some of this confusion arises from variable assay specificity regarding what peptides are being measured. We studied whether (a) BNP assays demonstrated crossreactivity with NT-proBNP or proBNP, and (b) whether NTproBNP assays demonstrated crossreactivity with BNP or proBNP, by using 5 commercial BNP and 3 commercial NT-proBNP assays with 2 BNP, 2 NT-proBNP, and 2 proBNP materials.
The NPs studied were: Peptide Institute synthetic BNP (aa 77-108), Scios human recombinant BNP (aa 77-108), HyTest human recombinant NT-proBNP (aa 1-76), Roche modified (amidated for stabilization) synthetic NTproBNP, HyTest human recombinant proBNP (aa 1-108), and Scios glycosylated human recombinant proBNP. BNP assays evaluated were Abbott Architect, Abbott AxSYM, Bayer Centaur, Biosite Triage, and Beckman Access (Biosite assay packaged for use by Beckman). NT-proBNP assays (all based on Roche reagents) were Dade-Behring Dimension, OrthoClinical Diagnostics Vitros, and Roche Elecsys 2010. All assays, for which epitopes of the antibodies used have been previous described (3 ), were run according to the manufacturers' guidelines. BNP, NT-proBNP, and proBNP materials were diluted with normal (low NP concentration) EDTAplasma pools and lithium-heparin plasma (Dade assay only) pools, collected from healthy donors after institutional review board approval was obtained, to achieve target concentrations of 250, 500, and 1000 ng/L. Baseline BNP and NT-proBNP were quantified first in the pools and then after the pools were spiked with NP peptides. All measurements were performed in duplicate. Baseline BNP or NT-proBNP concentrations were subtracted from each spiked pool measurement. Percent crossreactivity was calculated by dividing the measured concentration for the spiked pool into the expected peptide concentration, multiplying by 100, and then averaging across all 3 expected concentrations.
Recoveries and cross-reactivity percentages between peptides and BNP and NT-proBNP assays are displayed in Table 1 . The BNP assays were more specific for the BNP peptides, with recovery ranging from 79% to 199%, compared to 5% to 38% cross-reactivity to the proBNP peptides and Ͻ1% to 7% cross-reactivity to the NTproBNP peptides. Similarly, the NT-proBNP assays were more specific for the NT-proBNP peptides, showing 47% to 243% recovery, with substantial crossreactivity to proBNP peptides (Ͻ1% to 249%), and no crossreactivity to the BNP peptides (Ͻ1% across all assays).
This study demonstrates that the BNP peptides used do not substantially cross-react with NTproBNP assays, and that the NTproBNP peptides do not substantially cross-react with BNP assays. We confirm that there is substantial cross-reactivity between proBNP peptides and commercially available BNP and NT-proBNP assays. Variations depended on the different sources and types of peptide tested in each assay. We observed minimal crossreactivity with the glycosylated Scios proBNP peptide, compared with substantial cross-reactivity to the nonglycosylated HyTest proBNP peptide with the NTproBNP assays. Glycosylation likely interfered with peptide antibody binding. The mechanisms responsible for different reactivities between the HyTest and Roche NTproBNP peptides using different NT-proBNP assays, which use the same antibodies but different assay architectures, cannot be explained presently. The modest differences in reactivities for the recombinant (Scios) and synthetic (Peptide Institute) BNP materials using different BNP assays also requires additional study; with different assay architectures for the same reagents (Biosite, Beckman) showing diverse recovery.
Little is known about which NP forms are circulating physiologically. The clinical significance of measured cross-reactivities will Letters also depend on the relative quantities of different molecular forms found in individual patient blood. Mass spectrometry has shown that mature BNP1Ϫ32 is absent in severe heart failure patients, but a commercial assay still detected the presence of BNP1Ϫ32 (4 ). Glycosylated forms of proBNP in heart failure patients have also been found, along with uncleaved proBNP (1, 5 ) . Expression of the multiple forms that circulate during acute and chronic heart failure must be investigated in future studies to ensure that commercial assays are measuring the appropriate diagnostic biomarkers for heart failure. Our preliminary observations challenge the analytical field to better characterize what immunoassays measure and challenge the clinical field to better understand what molecules are measured and how to best interpret both BNP and NT-proBNP findings in regard to patient care. 
The severity of Hashimoto disease (HD) varies among patients and is difficult to predict when the disease is in the subclinical state and diagnosed by the presence of thyroid-specific autoantibody. Likewise, the intractability of Graves disease (GD) is difficult to predict. Autoimmune thyroid destruction that underlies both diseases is strongly determined by T-cell cytotoxicity, which is activated by interferon (IFN)-␥ (1 ) , and the T allele in ϩ874A/T polymorphism of the interferon gamma (IFNG) gene, which promotes increased IFN-␥ production, has been noted more frequently among patients with severe HD (2 ) . Cytokine balance between T-helper 1 (Th1) cytokines, such as IFN-␥, and Th2 cytokines is important in immune regulation (3 ). Therefore, it is possible that Th2 cytokines may also affect the severity of HD and the intractability of GD. To clarify the association of these polymorphisms of the IL4 and IL4RA genes with HD severity and GD intractability, we performed genotyping using a direct sequencing reaction for Ϫ590C/T and TaqMan single-nucleotide polymorphism genotyping assays for Ile50Val in the following individuals: 35 patients Ͻ50 years old with HD who developed permanent hypothyroidism and were treated with L-thyroxine (rapid destruction type; severe HD), 39 euthyroid patients Ͼ50 years old with HD who were untreated (slow destruction type; mild HD), 50 euthyroid patients with GD who remained positive for antithyrotropin receptor antibody (TRAb) despite being on antithyroid drug treatment for Ͼ5 years (intractable GD), 26 patients with GD in remission who had been euthyroid and negative for TRAb for Ͼ2 years after cessation of antithyroid drug treatment, and 47 controls. All patients with HD were positive for antithyroid microsomal antibodies. All patients with GD showed increased TRAb concentrations and thyrotoxicosis when first diagnosed. All study participants were Japanese and unrelated. Written informed consent was obtained from all patients and controls, and the study protocol was approved by the Ethics Committee of Osaka University.
The frequency of the Ϫ590CC genotype in the IL4 gene among the patients with severe HD was 20.0%, whereas the frequency among the patients with mild HD was 0.0% (P ϭ 0.0037) ( Table 1) . If this finding is confirmed prospectively, a high percentage of HD patients with the IL-4 Ϫ590CC genotype would be expected to develop severe disease (hypothyroidism) before 50 years of age. A possible mechanism to explain this phenomenon is that in HD patients with the Ϫ590CC genotype, the proportion of IL-4 -producing T-helper cells is lower than that in HD patients with the Ϫ590TT or Ϫ590CT genotype (4 ), which results in higher activity of inflammatory Th1 cytokines and more rapid progression of thyroid destruction, followed by early development of hypothyroidism. Conversely, we found no association between the Ile50Val polymorphism in the IL4RA gene and HD severity (Table 1 ) despite the receptor activity being different among individuals with this polymorphism. Furthermore, we found no association between these IL4 and IL4RA gene polymorphisms and GD intractability (Table 1) ; however, GD is caused by TRAb and tends to be more intractable in pa-tients with higher TRAb concentrations. In this context, we also found no relationship between these polymorphisms and serum TRAb concentrations (data not shown).
In conclusion, the Ϫ590CC genotype in the IL4 gene appears to be a strong predictive factor for the development of hypothyroidism in HD.
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